Paper Details

  1. Home
  2. Paper Details

Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.

Author: BonanniBernardo, CassanoEnrico, CazzanigaMassimiliano, DecensiAndrea, GandiniSara, Guerrieri-GonzagaAliana, JohanssonHarriet, LienErnst A, LuiniAlberto, MacisDebora, OldaniSabina, PelosiGiuseppe, SerranoDavide

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The combination of anastrozole and tamoxifen is inferior to anastrozole alone in terms of disease-free survival. This may be due to an adverse pharmacokinetic interaction or a predominant estrogenic effect of tamoxifen under estrogen deprivation.
Paper Details　
Original Abstract of the Article :
In the Anastrozole, Tamoxifen Alone or in Combination trial, the combination arm was inferior to anastrozole alone in terms of disease-free survival possibly due to an adverse pharmacokinetic interaction or a predominant estrogenic effect of tamoxifen under estrogen deprivation. We assessed whether ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/1078-0432.CCR-09-1354

データ提供：米国国立医学図書館（NLM）

Biomarker Trial of Anastrozole, Tamoxifen, or Combination: A Camel's Quest for Breast Cancer Prevention

Breast cancer is a significant public health concern, and research continues to explore effective prevention strategies. This study investigates the role of anastrozole and tamoxifen, two commonly used medications for breast cancer prevention, in patients with breast intraepithelial neoplasia (a precancerous condition). The researchers conducted a biomarker trial to assess the effects of these medications on various biomarkers associated with bone fracture, breast cancer, cardiovascular disease, and endometrial cancer risk.

A Camel's Journey Through the Desert of Biomarkers: Unveiling the Secrets of Breast Cancer Prevention

The study found that the combination of anastrozole and tamoxifen may not be as effective as anastrozole alone in preventing disease-free survival. The authors investigated the potential influence of a lower dose of tamoxifen on anastrozole bioavailability and its impact on various biomarkers. They also explored the role of CYP2D6 genotype, a gene involved in drug metabolism, in modulating tamoxifen effects. The results suggest that further research is needed to optimize the use of these medications for breast cancer prevention.

A Camel's Guide to Breast Cancer Prevention: Staying Safe in the Desert

Breast cancer prevention is a multifaceted endeavor. This study highlights the importance of ongoing research to understand the optimal use of medications like anastrozole and tamoxifen. It emphasizes the need for personalized approaches to breast cancer prevention, considering individual factors such as genetic predisposition and drug metabolism. Regular screenings and discussions with your healthcare provider are crucial for maintaining good breast health.

Dr. Camel's Conclusion

This research provides valuable insights into the complex interplay between anastrozole, tamoxifen, and biomarkers associated with breast cancer prevention. While further research is needed to optimize the use of these medications, this study highlights the importance of personalized approaches and emphasizes the need for ongoing research to combat this devastating disease.

Date :
  1. Date Completed 2010-03-22
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

19887477

DOI: Digital Object Identifier

10.1158/1078-0432.CCR-09-1354

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.